Atara biotherapeutics reports inducement grants under nasdaq listing rule 5635(c)(4)

South san francisco, calif.--(business wire)--atara biotherapeutics, inc. (nasdaq: atra), a pioneer in t-cell immunotherapy, leveraging its novel allogeneic ebv t-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune disease, today reported the grant of an aggregate of 52,019 restricted stock units of atara's common stock to 24 newly hired employees and stock options to purchase an aggregate of 82,342 shar
ATRA Ratings Summary
ATRA Quant Ranking